Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

NCT00768612 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SCA-136 50mg/day
DRUG: SCA-136 150 mg/day
DRUG: SCA-136 300mg/day
DRUG: Risperidone 4mg/day

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer